KR102448455B1 - 셀레노유기 화합물의 조성물 및 이의 사용 방법 - Google Patents

셀레노유기 화합물의 조성물 및 이의 사용 방법 Download PDF

Info

Publication number
KR102448455B1
KR102448455B1 KR1020167024957A KR20167024957A KR102448455B1 KR 102448455 B1 KR102448455 B1 KR 102448455B1 KR 1020167024957 A KR1020167024957 A KR 1020167024957A KR 20167024957 A KR20167024957 A KR 20167024957A KR 102448455 B1 KR102448455 B1 KR 102448455B1
Authority
KR
South Korea
Prior art keywords
compound
composition
compounds
cells
formula
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020167024957A
Other languages
English (en)
Korean (ko)
Other versions
KR20160125989A (ko
Inventor
로난 파워
지-지안 란
알렉산드로스 야니코우리스
Original Assignee
올텍 법인회사
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 올텍 법인회사 filed Critical 올텍 법인회사
Priority to KR1020217021039A priority Critical patent/KR102466389B1/ko
Publication of KR20160125989A publication Critical patent/KR20160125989A/ko
Application granted granted Critical
Publication of KR102448455B1 publication Critical patent/KR102448455B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7135—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/28—Compounds containing heavy metals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D473/00—Heterocyclic compounds containing purine ring systems
    • C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
    • C07D473/32—Nitrogen atom
    • C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Inorganic Chemistry (AREA)
  • Saccharide Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
KR1020167024957A 2014-03-14 2014-03-14 셀레노유기 화합물의 조성물 및 이의 사용 방법 Active KR102448455B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217021039A KR102466389B1 (ko) 2014-03-14 2014-03-14 셀레노유기 화합물의 조성물 및 이의 사용 방법

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2014/029542 WO2015137983A1 (en) 2014-03-14 2014-03-14 Compositions of selenoorganic compounds and methods of use thereof

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217021039A Division KR102466389B1 (ko) 2014-03-14 2014-03-14 셀레노유기 화합물의 조성물 및 이의 사용 방법

Publications (2)

Publication Number Publication Date
KR20160125989A KR20160125989A (ko) 2016-11-01
KR102448455B1 true KR102448455B1 (ko) 2022-09-28

Family

ID=54072241

Family Applications (3)

Application Number Title Priority Date Filing Date
KR1020167024957A Active KR102448455B1 (ko) 2014-03-14 2014-03-14 셀레노유기 화합물의 조성물 및 이의 사용 방법
KR1020217021039A Active KR102466389B1 (ko) 2014-03-14 2014-03-14 셀레노유기 화합물의 조성물 및 이의 사용 방법
KR1020160117539A Active KR102764247B1 (ko) 2014-03-14 2016-09-12 셀레노유기 화합물의 조성물 및 그의 사용 방법

Family Applications After (2)

Application Number Title Priority Date Filing Date
KR1020217021039A Active KR102466389B1 (ko) 2014-03-14 2014-03-14 셀레노유기 화합물의 조성물 및 이의 사용 방법
KR1020160117539A Active KR102764247B1 (ko) 2014-03-14 2016-09-12 셀레노유기 화합물의 조성물 및 그의 사용 방법

Country Status (16)

Country Link
US (3) US10201559B2 (enExample)
EP (1) EP3116511B1 (enExample)
JP (2) JP6313479B2 (enExample)
KR (3) KR102448455B1 (enExample)
CN (3) CN106456658A (enExample)
AU (4) AU2014386236B2 (enExample)
BR (1) BR112016020233B1 (enExample)
CA (1) CA2940283C (enExample)
DK (2) DK3116511T3 (enExample)
HU (2) HUE051713T2 (enExample)
IL (1) IL247312A0 (enExample)
MX (2) MX2016011897A (enExample)
PE (1) PE20211069A1 (enExample)
PT (1) PT3116511T (enExample)
RU (2) RU2665135C2 (enExample)
WO (2) WO2015137983A1 (enExample)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102448455B1 (ko) 2014-03-14 2022-09-28 올텍 법인회사 셀레노유기 화합물의 조성물 및 이의 사용 방법
CA2981138A1 (en) 2015-03-27 2016-10-06 The Research Foundation For The State University Of New York Methods and materials for reducing amyloid beta levels within a mammal
WO2017048252A1 (en) * 2015-09-15 2017-03-23 Alltech, Inc. Compositions of selenoorganic compounds and methods of use thereof
KR102054640B1 (ko) * 2015-09-24 2019-12-11 서울대학교산학협력단 아데노신 유도체, 이의 제조방법 및 이를 유효성분으로 함유하는 암의 예방 또는 치료용 약학적 조성물
AU2017234662A1 (en) * 2016-03-14 2018-10-04 Mitogenetics, Llc Materials and methods for treating hypoxic conditions
CN110545822A (zh) * 2017-05-19 2019-12-06 全技术公司 药剂、组合物及其相关方法
EP3661600A4 (en) 2017-10-23 2021-08-11 Epitracker, Inc. FATTY ACID ANALOGS AND ITS USE IN THE TREATMENT OF DISEASES RELATED TO METABOLISM SYNDROME
KR102083180B1 (ko) 2017-11-09 2020-03-02 서울대학교산학협력단 셀레노사마필린 a와 그 유도체, 이의 제조방법, 및 이를 유효성분으로 포함하는 암 예방 및 치료용 조성물
WO2019093699A1 (ko) * 2017-11-09 2019-05-16 서울대학교 산학협력단 셀레노사마필린 a와 그 유도체, 이의 제조방법 및 이를 유효성분으로 포함하는 암 예방 및 치료용 조성물
CN108484690B (zh) * 2018-05-16 2021-04-30 新乡拓新药业股份有限公司 一种1,2,3-三-O-乙酰基-5-脱氧-β-D-核糖的制备方法
JP2021525249A (ja) 2018-05-23 2021-09-24 エピトラッカー インコーポレイテッドＥｐｉｔｒａｃｋｅｒ， Ｉｎｃ． 加齢及び長期性の質に関連する状態の診断及び治療のための組成物及び方法
WO2020146263A1 (en) * 2019-01-09 2020-07-16 Epitracker, Inc. Compositions and methods for diagnosis and treatment of neurodegenerative diseases
JP7404382B2 (ja) 2019-03-04 2023-12-25 エピトラッカー インコーポレイテッド 脂肪酸アナログ、ならびに認知機能障害、行動症状および慢性疼痛の処置におけるそれらの使用
CN111543641A (zh) * 2020-04-27 2020-08-18 江苏惠利生物科技有限公司 一种提高l-硒-甲基硒代半胱氨酸稳定性以及生物利用率的方法
US20230277549A1 (en) * 2020-07-23 2023-09-07 Purdue Research Foundation Notch signaling inhibitors for treating obesity and metabolic disorders
EP4426130A1 (en) 2021-11-03 2024-09-11 Epitracker, Inc. Pentadecanoylcarnitine for treatment of conditions related to the quality of aging and longevity
JP2023076373A (ja) * 2021-11-22 2023-06-01 マルサンアイ株式会社 アミロイドβ凝集抑制剤とこれを含む医薬組成物および飲食品、ネプリライシン産生促進剤およびγ－セクレターゼ産生抑制剤
CN116333302B (zh) * 2023-03-31 2024-09-10 中南大学 一种稳定持久抗氧化纳米点及其在二型糖尿病中的应用
CN116421618B (zh) * 2023-06-15 2023-09-29 暨南大学 Se@NADH的制备方法及其在脊髓损伤治疗中的应用
US12285412B1 (en) 2024-12-27 2025-04-29 Imam Mohammad Ibn Saud Islamic University Organoselenium benzimidazole compounds for treating cancer

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122491A1 (en) 2005-10-14 2007-05-31 Alltech, Inc. Methods and compositions for altering cell function
US20120094947A1 (en) 2007-08-29 2012-04-19 Adam Lubin Method for the selective therapy of disease
WO2014144776A1 (en) 2013-03-15 2014-09-18 Alltech, Inc. Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5223263A (en) 1988-07-07 1993-06-29 Vical, Inc. Liponucleotide-containing liposomes
US5411947A (en) 1989-06-28 1995-05-02 Vestar, Inc. Method of converting a drug to an orally available form by covalently bonding a lipid to the drug
US5463092A (en) 1989-11-22 1995-10-31 Vestar, Inc. Lipid derivatives of phosphonacids for liposomal incorporation and method of use
US7517858B1 (en) 1995-06-07 2009-04-14 The Regents Of The University Of California Prodrugs of pharmaceuticals with improved bioavailability
US6312662B1 (en) 1998-03-06 2001-11-06 Metabasis Therapeutics, Inc. Prodrugs phosphorus-containing compounds
US6752981B1 (en) 1999-09-08 2004-06-22 Metabasis Therapeutics, Inc. Prodrugs for liver specific drug delivery
BR0016058A (pt) 1999-12-03 2003-07-15 Univ California San Diego Compostos de fosfonato
CA2397203A1 (en) 2000-03-31 2001-10-11 Sandra C. Tobias Phosphoramidate prodrugs
JP4942915B2 (ja) 2002-04-26 2012-05-30 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖプロテアーゼ阻害剤化合物のホスホネートアナログの細胞蓄積
EP1504014B1 (en) 2002-05-13 2015-12-02 Metabasis Therapeutics, Inc. Process for preparation of cyclic prodrugs of pmea and pmpa
IL164809A0 (en) 2002-05-13 2005-12-18 Metabasis Therapeutics Inc Novel phosphonic acid basdrugs of pmea and its analogues
PL214402B1 (pl) * 2003-08-11 2013-07-31 Tomasz Byrski Zastosowanie selenu albo jego zwiazku do otrzymywania srodka do obnizania odziedziczonego ryzyka zachorowania na raka piersi lub jajnika
WO2005023274A1 (en) 2003-09-05 2005-03-17 Yissum Research Development Company Of The Hebrew University Of Jerusalem Treatment and prevention of inflammatory disease and mitochondrial dysfunction with high dose selenium
JP2006151965A (ja) * 2004-10-28 2006-06-15 Mi Tec:Kk セレン含有組成物及びその製法
EP1652519A1 (en) 2004-10-28 2006-05-03 Tamie Nasu Seleniferous composition for producing antioxidase in vivo
EP1841748B1 (en) * 2004-12-31 2011-12-28 Seoul National University Industry Foundation Organoselenium containing compounds and their use
US20060198906A1 (en) 2005-03-07 2006-09-07 Sami Labs Limited Compositions and Method to Increase Serum Levels of HDL cholesterol and Lower the Risk of Cardiovascular Disease
US20070077238A1 (en) 2005-10-04 2007-04-05 Teo Alex Y Production of organic and inorganic selenium compounds by lactic acid bacteria
TWI319708B (en) 2005-10-14 2010-01-21 Methods and compositions for altering cell fuction
US20080004255A1 (en) 2005-10-14 2008-01-03 Alltech, Inc. Methods and compositions for altering cell function
CA2524551C (en) * 2005-10-14 2014-12-16 Alltech, Inc. Use of selenium yeasts in the treatment of alzheimer's disease
CN101045048B (zh) * 2006-03-27 2011-05-18 中国科学院上海生命科学研究院 线粒体营养素组合物的应用
CA2650309C (en) 2006-04-24 2014-08-19 Alltech, Inc. Selenium-containing compositions and use of the same
WO2009026949A1 (en) * 2007-08-31 2009-03-05 Dsm Ip Assets B.V. 4-amidino benzylamines for cosmetic and/or dermatological use
EP2220208A4 (en) * 2007-11-23 2010-12-29 Rappaport Family Inst For Res USE OF HAPTOGLOBIN ENTYPIZATION FOR THE DIAGNOSIS AND TREATMENT OF CARDIOVASCULAR DISEASES
CN101289495A (zh) * 2008-05-23 2008-10-22 浙江大学 含硒五肽化合物及其应用
EP2490711A4 (en) * 2009-10-22 2013-04-03 Propanc Pty Ltd PHARMACEUTICAL COMPOSITION FOR CREATING TREATMENT WITH TRYPSINOGENES AND / OR CHYMOTRYPINOGENS AND AN ACTIVE COMPOUNDS SELECTED FROM A SELENIC COMPOUND, A VANILLOID COMPOUND AND A CYTOPLASMIC GLYCOLYSIDE DEDICATOR
JP5510302B2 (ja) * 2010-12-15 2014-06-04 トヨタ紡織株式会社 接続部材、その製造方法及び接続構造体
WO2012130609A1 (en) * 2011-04-01 2012-10-04 Iasomai Ab New combination comprising n-acetyl-l-cysteine and its use
WO2013151975A1 (en) 2012-04-02 2013-10-10 Northeastern University Compositions and methods for the inhibition of methyltransferases
NL2010222C2 (en) * 2013-02-01 2014-08-04 Conradus Ghosal Gho Composition and method for generating a desired cell type and/or tissue type from hair follicular stem cells.
KR102448455B1 (ko) 2014-03-14 2022-09-28 올텍 법인회사 셀레노유기 화합물의 조성물 및 이의 사용 방법
US20160000136A1 (en) * 2014-07-02 2016-01-07 Hamilton Beach Brands, Inc. Juice Extractor
US20160090397A1 (en) 2014-09-30 2016-03-31 Northeastern University Se-Adenosyl-L-Selenohomocysteine Selenoxide As A Modulator Of Methyltransferase And Other Activities

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070122491A1 (en) 2005-10-14 2007-05-31 Alltech, Inc. Methods and compositions for altering cell function
US20120094947A1 (en) 2007-08-29 2012-04-19 Adam Lubin Method for the selective therapy of disease
WO2014144776A1 (en) 2013-03-15 2014-09-18 Alltech, Inc. Compositions comprising selenium and use of same for the treatment and prevention of disease or conditions associated with mitochondrial dysfunction

Also Published As

Publication number Publication date
AU2014386236A1 (en) 2016-09-01
AU2016222315A1 (en) 2017-03-30
KR20170032862A (ko) 2017-03-23
US20160045533A1 (en) 2016-02-18
EP3116511B1 (en) 2020-08-26
MX2016011898A (es) 2018-03-12
CN106822168A (zh) 2017-06-13
EP3116511A1 (en) 2017-01-18
NZ723402A (en) 2024-11-29
BR112016020233A2 (enExample) 2017-08-15
US10201558B2 (en) 2019-02-12
RU2665135C2 (ru) 2018-08-28
JP7009053B2 (ja) 2022-01-25
RU2016133469A (ru) 2018-04-17
JP2017512828A (ja) 2017-05-25
US10201559B2 (en) 2019-02-12
AU2019246818A1 (en) 2019-10-31
RU2731383C2 (ru) 2020-09-02
KR20160125989A (ko) 2016-11-01
HUE051713T2 (hu) 2021-03-29
JP2017078056A (ja) 2017-04-27
US9642874B2 (en) 2017-05-09
KR102764247B1 (ko) 2025-02-07
CA2940283A1 (en) 2015-09-17
WO2017048253A1 (en) 2017-03-23
WO2015137983A1 (en) 2015-09-17
CN106456658A (zh) 2017-02-22
DK3116511T3 (da) 2020-11-23
CN113694074A (zh) 2021-11-26
EP3116511A4 (en) 2017-10-18
CA2940283C (en) 2021-03-30
RU2016136530A (ru) 2018-03-16
KR102466389B1 (ko) 2022-11-11
PE20211069A1 (es) 2021-06-09
AU2019246818B2 (en) 2021-02-25
CN106822168B (zh) 2020-11-27
PT3116511T (pt) 2020-11-19
BR112016020233B1 (pt) 2022-07-19
NZ723233A (en) 2020-10-30
KR20210104070A (ko) 2021-08-24
IL247312A0 (en) 2016-09-29
BR102016021058A2 (pt) 2017-05-30
JP6313479B2 (ja) 2018-04-18
AU2014386236B2 (en) 2019-07-11
MX2016011897A (es) 2017-04-27
DK3144001T3 (da) 2021-11-15
AU2016222315B2 (en) 2022-08-04
AU2022204588A1 (en) 2022-07-21
US20160082033A1 (en) 2016-03-24
US20160361338A1 (en) 2016-12-15
RU2016136530A3 (enExample) 2019-11-25
HUE056172T2 (hu) 2022-01-28

Similar Documents

Publication Publication Date Title
KR102448455B1 (ko) 셀레노유기 화합물의 조성물 및 이의 사용 방법
CA2939592C (en) Compositions of selenoorganic compounds and methods of use thereof
HK40064580A (en) Compositions of selenoorganic compounds and methods of use thereof
HK1233497B (en) Compositions of selenoorganic compounds and methods of use thereof
NZ723233B2 (en) Compositions of selenoorganic compounds and methods of use thereof
HK1235284B (en) Compositions of selenoorganic compounds and methods of use thereof
BR102016021058B1 (pt) Uso de uma composição e método para modular o metabolismo de glicose em células do fígado
HK1235284A1 (en) Compositions of selenoorganic compounds and methods of use thereof

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

R18-X000 Changes to party contact information recorded

St.27 status event code: A-3-3-R10-R18-oth-X000

A201 Request for examination
AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

R17-X000 Change to representative recorded

St.27 status event code: A-3-3-R10-R17-oth-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

St.27 status event code: A-1-2-D10-D21-exm-PE0902

AMND Amendment
E13-X000 Pre-grant limitation requested

St.27 status event code: A-2-3-E10-E13-lim-X000

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

E601 Decision to refuse application
PE0601 Decision on rejection of patent

St.27 status event code: N-2-6-B10-B15-exm-PE0601

X091 Application refused [patent]
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

AMND Amendment
P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000

P13-X000 Application amended

St.27 status event code: A-2-2-P10-P13-nap-X000

PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PX0901 Re-examination

St.27 status event code: A-2-3-E10-E12-rex-PX0901

PX0601 Decision of rejection after re-examination

St.27 status event code: N-2-6-B10-B17-rex-PX0601

X601 Decision of rejection after re-examination
T11-X000 Administrative time limit extension requested

St.27 status event code: U-3-3-T10-T11-oth-X000

T13-X000 Administrative time limit extension granted

St.27 status event code: U-3-3-T10-T13-oth-X000

J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

St.27 status event code: A-3-3-V10-V11-apl-PJ0201

J301 Trial decision

Free format text: TRIAL NUMBER: 2021101002415; TRIAL DECISION FOR APPEAL AGAINST DECISION TO DECLINE REFUSAL REQUESTED 20210917

Effective date: 20220523

PJ1301 Trial decision

St.27 status event code: A-3-3-V10-V15-crt-PJ1301

Decision date: 20220523

Appeal event data comment text: Appeal Kind Category : Appeal against decision to decline refusal, Appeal Ground Text : 2016 7024957

Appeal request date: 20210917

Appellate body name: Patent Examination Board

Decision authority category: Office appeal board

Decision identifier: 2021101002415

PS0901 Examination by remand of revocation

St.27 status event code: A-6-3-E10-E12-rex-PS0901

GRNO Decision to grant (after opposition)
PS0701 Decision of registration after remand of revocation

St.27 status event code: A-3-4-F10-F13-rex-PS0701

PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-OTH-PR1001 (AS PROVIDED BY THE NATIONAL OFFICE)

Year of fee payment: 4